Intervention

Empagliflozin

ClinicalTrials.gov intervention label

Clinical trials109

Recruiting9

Common conditions25

Lead sponsors shown15

Clinical trials

60 shown

A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and WarfarinNCT07331389 · 2025-09-24

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseaseNCT07064473 · 2025-07-22

Feasibility Trial for a Right Ventricular Failure Platform TrialNCT06570473 · 2025-07-15

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With ObesityNCT06745063 · 2025-05-30

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)NCT06024746 · 2024-07-09

Empagliflozin Treatment in Kidney Transplant RecipientsNCT06013865 · 2024-04-05

Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia PatientsNCT05669742 · 2023-05-25

Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE StudyNCT05164263 · 2021-04-01

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerNCT03424005 · 2018-03-30

Restoring Vascular and Insulin Function To Augment Anti-Amyloid Therapy in Alzheimer's DiseaseNCT07756294 · 2026-11-01

NOT_YET_RECRUITING

Empagliflozin Versus Non-SGLT2 Oral Drugs for Blood Pressure in Type 2 DiabetesNCT07541456 · 2025-06-09

HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed TherapyNCT06844669 · 2025-04-16

Antithrombotic Activities of Sotagliflozin vs. EmpagliflozinNCT06618976 · 2025-02-25

Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 DiabetesNCT06762314 · 2025-01-20

Emulation of the EMPEROR-Preserved Trial Using Healthcare Claims DataNCT07599293 · 2024-10-13

Emulation of the EMPEROR-Reduced Trial Using Healthcare Claims DataNCT07599345 · 2024-10-13

Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With MetforminNCT06571591 · 2024-08-27

Effectiveness of Empagliflozin Added to Automated Insulin Delivery (AID) Systems in Adults With Type 1 Diabetes With Sub-optimal Glycemic OutcomesNCT06021145 · 2024-04-02

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 DiabetesNCT06083675 · 2024-01-26

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related DiabetesNCT06149793 · 2024-01-08

ACTIVE_NOT_RECRUITING

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2DNCT05140694 · 2023-12-01

Empagliflozin and CPAP in Adults With Heart Failure and Obstructive Sleep Apnea.NCT07556094 · 2023-06-05

Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)NCT05757791 · 2023-03-17

Emp-Activity: Empagliflozin Functional CapacityNCT05350202 · 2022-12-18

Use of Empagliflozin to Treat PrediabetesNCT05426525 · 2022-10-13

LIGHT-MCI Trial: GLP-1 Agonist, SGLT2 Inhibitor, and DPP-4 Inhibitor for MCI Remission in Type 2 DiabetesNCT05313529 · 2022-10-08

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and ObesityNCT05444153 · 2022-10-06

Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney DiseaseNCT05465317 · 2022-08-08

Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes MellitusNCT05232071 · 2022-06-29

A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)NCT05282121 · 2022-06-28

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 DiabetesNCT05254002 · 2022-06-23

Impact of SGLT2 on Glucosuria in HNF1A-MODYNCT05417646 · 2022-06-22

Canagliflozin in Patients With Acute Decompansted Heart FailureNCT05364190 · 2022-06-04

Cognitive Protective Effect of Newer Antidiabetic DrugsNCT05347459 · 2022-03-02

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty LiverNCT04976283 · 2021-09-15

Empagliflozin and Atrial Fibrillation TreatmentNCT04583813 · 2021-09-01

Empagliflozin in Adolescent DiabetesNCT04917692 · 2021-07-01

GliflOzin in eLderly Diabetic patiENts: A praGmatic Intraclass Evaluation TrialNCT04796428 · 2021-06-30

This Study Combines Data From 3 Other Studies Testing Empagliflozin in Patients With Diabetes or With Chronic Heart Failure. The Study Looks at the Numbers of Patients Who Had Lower Limb AmputationsNCT04937816 · 2021-06-01

Empagliflozin and Cardiac Remodelling in People Without DiabetesNCT04461041 · 2021-04-01

EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction)NCT04509674 · 2020-12-16

Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASHNCT04702490 · 2020-12-15

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor AgonistsNCT04295005 · 2020-11-16

A Study to Test How Well Empagliflozin Works in Japanese People With Type 2 Diabetes Who Are Older Than 65 YearsNCT04531462 · 2020-10-05

Pharmacokinetic Drug Interaction Between Teneligliptin and EmpagliflozinNCT04431141 · 2020-09-15

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes MellitusNCT05359432 · 2020-07-01

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart FailureNCT04157751 · 2020-05-18

A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take InsulinNCT04233801 · 2020-04-15

A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 DiabetesNCT04098575 · 2019-09-16

Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes MellitusNCT04014192 · 2019-09-01

DIA_CENTRAL:T2D Treatment Pattern in Central EuropeNCT03807440 · 2019-08-26

Replication of the EMPAREG Diabetes Trial in Healthcare ClaimsNCT04215536 · 2019-07-08

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes MellitusNCT04665284 · 2019-06-01

Drug Interaction Study Between Dorzagliatin and EmpagliflozinNCT03790787 · 2019-04-18

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes MellitusNCT03753087 · 2019-01-16

Antidiabetic Drugs for Steatotic Liver DiseaseNCT03646292 · 2018-12-06

A Study Using Medical Records of Danish People With Type 2 Diabetes Comparing Empagliflozin and Glucagon-Like Peptide-1 Receptor Agonists (GLP1-RA) in the Occurrence of Serious Cardiovascular OutcomesNCT03993132 · 2018-10-01

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and DehydrationNCT03764631 · 2018-09-26

Efficacy and Safety of Empagliflozin in NODATNCT03642184 · 2018-07-14

EMPA Acute Heart FailureNCT03554200 · 2018-06-11

Common conditions

Leading sponsors

Boehringer Ingelheim31 Getz Pharma4 Brigham and Women's Hospital3 Hannover Medical School2 Icahn School of Medicine at Mount Sinai2 Janssen Research & Development, LLC2 Novo Nordisk A/S2 Profil Institut für Stoffwechselforschung GmbH2 RWTH Aachen University2 Steno Diabetes Center Copenhagen2 Unity Health Toronto2 VA Office of Research and Development2 Yonsei University2 Alexandria University1 Bayer1

Trial status mix

COMPLETED74

UNKNOWN11

RECRUITING9

TERMINATED7

WITHDRAWN6

ACTIVE_NOT_RECRUITING1

NOT_YET_RECRUITING1

Phase mix

PHASE435

PHASE325

PHASE219

NA6

PHASE16

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.